Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 232

Results For "IT"

10347 News Found

PM chairs high-level meeting to asses situation of Covid-19 & Influenza
Policy | March 23, 2023

PM chairs high-level meeting to asses situation of Covid-19 & Influenza

PM emphasises the need to enhance lab surveillance & testing of all Severe Acute Respiratory Illness (SARI) cases & ramp up genome sequencing


Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study
Clinical Trials | March 23, 2023

Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study

The data from this study show that MM-II has the potential to provide durable pain relief for our patients


Zydus receives final and tentative approval from USFDA for Tofacitinib Tablets
Drug Approval | March 22, 2023

Zydus receives final and tentative approval from USFDA for Tofacitinib Tablets

Tofacitinib Tablets, 5 mg and 10 mg had annual sales of US $900 million in the United States (IQVIA MAT December 2022)


Granules Consumer Health concludes FDA audit with zero observations
Drug Approval | March 22, 2023

Granules Consumer Health concludes FDA audit with zero observations

The audit is a pre-approval inspection for three products filed from the facility


Serum Institute of India likely front-runner to win supply of HPV vaccines for UIP, says GlobalData
News | March 21, 2023

Serum Institute of India likely front-runner to win supply of HPV vaccines for UIP, says GlobalData

The Indian government will float a global tender in April 2023 to procure HPV vaccines.


Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing
Clinical Trials | March 21, 2023

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing

All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking


Patritumab Deruxtecan shows better clinical activity in patient with lung and breast cancer
Clinical Trials | March 20, 2023

Patritumab Deruxtecan shows better clinical activity in patient with lung and breast cancer

Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session


Phase 3 data show Deuruxolitinib significantly improve scalp hair regrowth in Alopecia Areata
News | March 20, 2023

Phase 3 data show Deuruxolitinib significantly improve scalp hair regrowth in Alopecia Areata

The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022


Bliss GVS Pharma gets 3 minor observations from USFDA for Palghar unit
Drug Approval | March 19, 2023

Bliss GVS Pharma gets 3 minor observations from USFDA for Palghar unit

The observations are procedural in nature


Lupin Digital Health reveals results of digital therapeutics study with ACS patients
Digitisation | March 18, 2023

Lupin Digital Health reveals results of digital therapeutics study with ACS patients

The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform